77 related articles for article (PubMed ID: 8729907)
21. [Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3].
Ren SH; Zhang W; Qu P; Liu Y; Wang JW; Zhang L
Ai Zheng; 2005 Oct; 24(10):1173-8. PubMed ID: 16219128
[TBL] [Abstract][Full Text] [Related]
22. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB
Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724
[TBL] [Abstract][Full Text] [Related]
23. Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.
Rosenfeld ME; Rogers BE; Khazaeli MB; Mikheeva G; Raben D; Mayo MS; Curiel DT; Buchsbaum DJ
Clin Cancer Res; 1997 Jul; 3(7):1187-94. PubMed ID: 9815798
[TBL] [Abstract][Full Text] [Related]
24. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
Grim J; Deshane J; Feng M; Lieber A; Kay M; Curiel DT
Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
[TBL] [Abstract][Full Text] [Related]
25. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells.
You XL; Yen L; Zeng-Rong N; Al Moustafa AE; Alaoui-Jamali MA
Oncogene; 1998 Dec; 17(24):3177-86. PubMed ID: 9872333
[TBL] [Abstract][Full Text] [Related]
26. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
[TBL] [Abstract][Full Text] [Related]
27. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
Wiechen K; Karaaslan S; Turzynski A; Dietel M
Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
[TBL] [Abstract][Full Text] [Related]
28. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
29. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
30. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
31. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
32. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7.
Piché A; Grim J; Rancourt C; Gómez-Navarro J; Reed JC; Curiel DT
Cancer Res; 1998 May; 58(10):2134-40. PubMed ID: 9605757
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
[TBL] [Abstract][Full Text] [Related]
34. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.
Alaoui-Jamali MA; Song DJ; Benlimame N; Yen L; Deng X; Hernandez-Perez M; Wang T
Cancer Res; 2003 Jul; 63(13):3764-74. PubMed ID: 12839972
[TBL] [Abstract][Full Text] [Related]
35. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects.
Wang-Johanning F; Gillespie GY; Grim J; Rancourt C; Alvarez RD; Siegal GP; Curiel DT
Cancer Res; 1998 May; 58(9):1893-900. PubMed ID: 9581830
[TBL] [Abstract][Full Text] [Related]
36. Targeted gene delivery to mammalian cells by filamentous bacteriophage.
Poul MA; Marks JD
J Mol Biol; 1999 Apr; 288(2):203-11. PubMed ID: 10329137
[TBL] [Abstract][Full Text] [Related]
37. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
38. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ
Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122
[TBL] [Abstract][Full Text] [Related]
40. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
